article thumbnail

SABCS: Pharmas show their working in HR+/HER2- breast cancer

Pharma Phorum

There was also new data from the monarchE trial of Eli Lilly’s CDK 4/6 inhibitor Verzenio (abemaciclib) in combination with endocrine therapy as an adjuvant treatment for patients with high risk, early-stage HR+/HER2- breast cancer.

HR 105
article thumbnail

eBook: HR Development within the Life Sciences Industry

XTalks

Disruption is very commonly witnessed in the life sciences industry hence human resources (HR) departments need to continuously come up with new talent strategies and recruitment practices to stay progressive. . What exactly does the future of HR look like as digital transformation escalates?

HR 93
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2? metastatic breast cancer compared to chemotherapy

The Pharma Data

Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy. The study enrolled 222 patients with aggressive forms of HR+/HER2− MBC (i.e., months (HR=0.54; 95% CI: 0.36-0.79; p=.0007)

HR 98
article thumbnail

Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study

The Pharma Data

months; hazard rate( HR) = 0.79;( 95 confidence interval( CI)0.65-0.96); p = 0.02). Trodelvy has not been approved by any nonsupervisory agency for the treatment of HR/ HER2- metastatic bone cancer. About HR/ HER2- bone Cancer. – 3.2

HR 98
article thumbnail

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

Pharma Mirror

The post Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval appeared first on Pharma Mirror Magazine. Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an ?-specific

HR 130
article thumbnail

Capivasertib plus Faslodex significantly bettered progression-free survivalvs. Faslodex in CAPItello- 291 Phase III trial in advanced HR-positive bone cancer

The Pharma Data

roughly 70 of bone cancer tumours are considered HR-positive and HER2-low or negative.2 Endocrine curatives are extensively used for the treatment of HR-positive bone cancer, but numerous cases with advanced complaint develop resistance to 1st- line CDK4/ 6 impediments and estrogen receptor- targeting curatives, emphasizing the need for fresh options.3 Capivasertib plus Faslodex significantly bettered progression-free survivalvs.

HR 75
article thumbnail

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

BioTech 365

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast … Continue reading → Business Wire

HR 52
article thumbnail

U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer

The Pharma Data

Food and Drug Administration (FDA) approved an expanded indication for Verzenio ® (abemaciclib), in combination with endocrine therapy (ET), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at a high risk of recurrence. The addition of Verzenio to ET reduced the risk of recurrence by 35% compared to ET alone (HR=0.653 [95% CI: 0.567-0.753]).

HR 40
article thumbnail

Global HR+/HER2-VE Breast Cancer Pipeline Landscape Report 2021 – ResearchAndMarkets.com

BioTech 365

Global HR+/HER2-VE Breast Cancer Pipeline Landscape Report 2021 – ResearchAndMarkets.com Global HR+/HER2-VE Breast Cancer Pipeline Landscape Report 2021 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “HR+/HER2-VE Breast Cancer – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This HR+/HER2-VE Breast … Continue reading → Business Wire

HR 40
article thumbnail

Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services

BioTech 365

Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services CALGARY, Alberta–(BUSINESS WIRE)–#albertadentist–With businesses everywhere struggling to keep their doors … Continue reading → Business Wire

HR 40
article thumbnail

Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer

The Pharma Data

Nasdaq: GILD) today announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy ® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.

HR 52
article thumbnail

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease

BioTech 365

HR 52
article thumbnail

Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients

BioTech 365

HR 52
article thumbnail

^^BIORAD 7500502 Signal Importación Módulo Hr – Nuevo

BioTech 365

| Añadir a lista de seguimiento Biotech365 : ^^BIORAD 7500502 Signal Importación Módulo Hr – Nuevo BioMarketplace You want to propose your products or a Biotech … Continue reading → #BioMarketplace #BioMarketplace_ES #Biorad71,11 EURFecha de finalización: miércoles sep-16-2020 8:31:12 CESTCómpralo ya por sólo: 71,11 EUR¡Cómpralo ya! |

HR 40
article thumbnail

Can Your Employer Make You Get a Vaccine? A Conversation with an HR Consultant

BioSpace

We interviewed Krissy Fuller, a human resources consultant, to learn more about the issue of mandated vaccines from an HR perspective and shared her predictions on what changes she thinks will last after the pandemic

HR 59
article thumbnail

Regional Business Leaders Warn of Tremendous Loss of Jobs, Economic Output from H.R. 3

BioTech 365

Regional Business Leaders Warn of Tremendous Loss of Jobs, Economic Output from H.R. 3 Regional Business Leaders Warn of Tremendous Loss of Jobs, Economic Output from H.R.

HR 52
article thumbnail

Increasing the Business Value of Your HR Data: Integrate to Innovate

XTalks

HR organizations rely on access to employee data to address regulatory requirements, support modernization projects, manage talent, and address mergers and acquisitions. Why is having the right HR technology so important?

HR 66
article thumbnail

Piqray and Faslodex combo extends survival in HR+/HER2-, PIK3CA+ advanced breast cancer at ESMO 2020

The Pharma Data

New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer in patients whose tumours are PIK3CA positive.

HR 52
article thumbnail

SET2,3 index can be prognostic in HR+ breast cancer, independent of recurrence score

Scienmag

Credit: SWOG/The Hope Foundation In an analysis of data from postmenopausal patients with hormone receptor-positive breast cancer, a standard measure of gene expression known as the sensitivity-to-endocrine-therapy (SET2,3) index was found to have prognostic value that complemented the known prognostic value of the 21-gene breast recurrence score.

HR 80
article thumbnail

FIRST-LINE IBRANCE® (PALBOCICLIB) COMBINATION THERAPY IN HR+, HER2- METASTATIC BREAST CANCER

The Pharma Data

months with letrozole alone (HR 0.58: 95% CI, 0.49 months among patients in the letrozole group (HR 0.66: 95% CI, 0.53 This real-world cohort includes more than 1,400 women with HR+, HER2- mBC with any extent of visceral disease.

HR 52
article thumbnail

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

BioTech 365

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer With the MONALEESA-2 final analysis, only … Continue reading → GlobeNewswire

HR 52
article thumbnail

BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada

BioTech 365

BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada OTTAWA, Ontario–(BUSINESS … Continue reading → Business Wire

HR 52
article thumbnail

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

BioTech 365

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i New data underscore efficacy … Continue reading → GlobeNewswire

HR 40
article thumbnail

How Has COVID-19 Changed the Way We Work in the Life Sciences?

XTalks

Xtalks spoke with two HR professionals to find out how companies are handling the transition from a work-from-home policy to a hybrid or back-to-work model. News Blogs Career Insights Blogs Featured Pandemic Highlight COVID-19 Life Science Jobs HR

article thumbnail

First new drug in years reduces recurrence in high risk HR+ early breast cancer

Scienmag

Data from latest research presented at the ESMO Virtual Congress 2020 Lugano, Switzerland, 20 September 2020 – Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study […].

article thumbnail

Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer

BioTech 365

Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer Results from pre-planned subgroup … Continue reading → GlobeNewswire

HR 40
article thumbnail

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020

BioTech 365

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast … Continue reading → Business Wire

HR 52
article thumbnail

Life Science Careers: Leveraging AI in Talent Acquisition and Industry Expertise for Employers and Employees

XTalks

Therefore, the role of HR is critical at any organization. And on February 19, join An Insider’s Look: How Syneos Health is Shortening the Distance from Lab to Life in Clinical Trials for key industry HR insights for jobseekers. This includes hiring practices and HR management.

article thumbnail

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation

BioTech 365

In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to fulvestrant alone1 14+ months OS improvement was achieved in … Continue reading → GlobeNewswire

HR 40
article thumbnail

FDA grants approval to Gilead Sciences’ breast cancer therapy

Pharmaceutical Technology

Trodelvy has been approved for HR+/HER2- breast cancer adult patients who have previously received endocrine-based therapy and a minimum of two additional systemic therapies in the metastatic setting.

HR 264
article thumbnail

Health Canada gives approval to Enhertu for breast cancer treatment

Pharmaceutical Technology

The regulatory approval was based on the data obtained from the DESTINY-Breast04 Phase III trial, which was conducted in HR-positive or HR-negative, HER2-low unresectable or metastatic breast cancer patients, who have received one or two prior lines of chemotherapy.

HR 321
article thumbnail

NTU launches two new programs to develop human resource talent with Institute for Human Resource Professionals

Scienmag

Credit: NTU Singapore Nanyang Technological University, Singapore (NTU Singapore) is collaborating with the Institute for Human Resource Professionals (IHRP) to launch two new MiniMasters™ programmes to develop talent in human resources (HR).

HR 89
article thumbnail

EU approves Daiichi Sankyo-AstraZeneca’s breast cancer therapy

Pharmaceutical Technology

The European Union (EU) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (trastuzumab deruxtecan) as monotherapy to treat unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer adult patients.

HR 235
article thumbnail

US FDA approves expanded indication for Lilly’s breast cancer therapy

Pharmaceutical Technology

Verzenio along with endocrine therapy (ET) has received approval as an adjuvant treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) adult patients who are at a high recurrence risk.

HR 130
article thumbnail

Gilead's Trodelvy Data Leaves Some Questioning Clinical Advantage

BioSpace

Gilead Sciences shared what seemed to be good news regarding Trodelvy in HR+/HER2- breast cancer at the 2022 American Society of Clinical Oncology's annual meeting

HR 56
article thumbnail

Camizestrant significantly bettered progression-free survivalvs. Faslodex in SERENA- 2 Phase II trial in advanced ER-positive bone cancer

The Pharma Data

roughly 70 of bone cancer tumours are considered HR-positive and HER2-low or negative.2 In addition to these results, the Company has also blazoned moment positive results from the CAPitello- 291 Phase III trial of capivasertib in HR-positive advanced bone cancer.

HR 96
article thumbnail

ESMO 2022: shrinking market for Trodelvy, with fierce ADC competition

Pharmaceutical Technology

Hormone receptor-positive/human epidermal growth factor negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancers, with close to 40,000 new cases diagnosed each year worldwide.

HR 162
article thumbnail

Specialised Therapeutics’ breast cancer drug gets Philippines FDA approval

Pharmaceutical Technology

The company claimed that the utmost benefit is reported in hormone-receptor positive (HR+) women and those who commence treatment with Nerlynx within a year of receiving trastuzumab-based therapy.

article thumbnail

AcuraBio Appoints Talented Senior Executives to Drive Global Growth Program

Pharma Mirror

International biopharma executive Guillaume Herry has been appointed as CEO, while HR executive Joanne Reichardt has been appointed Head of People & Culture.

HR 130
article thumbnail

AstraZeneca-Daiichi Sankyo’s Enhertu gets US FDA approval for breast cancer

Pharmaceutical Technology

According to the trial data, Enhertu lowered disease progression or mortality risk by 50% compared with chemotherapy according to the physician’s choice in HER2-low metastatic breast cancer patients with hormone receptor (HR)-positive disease or HR-negative disease.

article thumbnail

Pfizer seeks approval from US FDA for Covid-19 treatment

Pharmaceutical Technology

The latest filing is based on non-clinical and clinical data for Paxlovid and also comprised data from the Phase II/III EPIC-HR clinical trial.

HR 264
article thumbnail

Lilly Announces Details of donations at 2022 San Antonio bone Cancer Symposium

The Pharma Data

The Verzenio oral and bill donations will give streamlined clinical data from ongoing studies in early and advanced forms of hormone receptor-positive( HR), mortal epidermal growth factor receptor 2-negative( HER2-) bone cancer. An oral donation will give results from apre-planned overall survival( zilches) analysis from the Phase 3 monarchE study in HR, HER2-, knot-positive, high threat early bone cancer, including four- time efficacity issues.

HR 75
article thumbnail

Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022

The Pharma Data

– Late-Breaking Presentation of Phase 3 TROPiCS-02 Study of Trodelvy ® Demonstrates Overall Survival Benefit in Pre-Treated HR+/HER2- Metastatic Breast Cancer –. About HR/ HER2- bone Cancer.

HR 98